RT Journal Article SR Electronic T1 The impact of hypoxia on B cells in COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.12.21260360 DO 10.1101/2021.07.12.21260360 A1 Prasanti Kotagiri A1 Federica Mescia A1 Aimee Hanson A1 Lorinda Turner A1 Laura Bergamaschi A1 Ana Peñalver A1 Nathan Richoz A1 Stephen D Moore A1 Brian M Ortmann A1 Benjamin J. Dunmore A1 Helene Ruffieux A1 Michael D Morgan A1 Zewen Kelvin Tuong A1 Rachael J M Bashford-Rogers A1 Myra Hosmillo A1 Stephen Baker A1 Anne Elmer A1 Ian G Goodfellow A1 Ravindra K. Gupta A1 Nathalie Kingston A1 Paul J. Lehner A1 Nicholas J. Matheson A1 Sylvia Richardson A1 Caroline Saunders A1 Michael P. Weekes A1 Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration A1 Berthold Göttgens A1 Mark Toshner A1 Christoph Hess A1 Patrick. H. Maxwell A1 Menna. R. Clatworthy A1 James A. Nathan A1 John R. Bradley A1 Paul A. Lyons A1 Natalie Burrows A1 Kenneth G.C. Smith YR 2021 UL http://medrxiv.org/content/early/2021/07/15/2021.07.12.21260360.abstract AB Prominent early features of COVID-19 include severe, often clinically silent, hypoxia and a pronounced reduction in B cells, the latter important in defence against SARS-CoV-2. This brought to mind the phenotype of mice with VHL-deficient B cells, in which Hypoxia-Inducible Factors are constitutively active, suggesting hypoxia might drive B cell abnormalities in COVID-19. We demonstrated the breadth of early and persistent defects in B cell subsets in moderate/severe COVID-19, including reduced marginal zone-like, memory and transitional B cells, changes we also observed in B cell VHL-deficient mice. This was corroborated by hypoxia-related transcriptional changes in COVID-19 patients, and by similar B cell abnormalities in mice kept in hypoxic conditions, including reduced marginal zone and germinal center B cells. Thus hypoxia might contribute to B cell pathology in COVID-19, and in other hypoxic states. Through this mechanism it may impact on COVID-19 outcome, and be remediable through early oxygen therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank all the patients and Health Care Workers who consented to take part in this study. We are grateful for the generous support of CVC Capital Partners, the Evelyn Trust (20/75), Addenbrookes Charitable Trust (12/20A), the NIHR Cambridge Biomedical Research Centre and the UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) for their financial support. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres (Grant codes: RG85445 and RG94028), NHS Trusts and staff for their contribution. We thank the National Institute for Health Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. We would like to thank: the NIHR Cambridge Clinic Research Facility outreach team for enrolment of patients; the NIHR Cambridge Biomedical Research Centre Cell Phenotyping Hub and the CRUK Cambridge Institute flow cytometry core facility for their support with flow and mass cytometry; and the Cambridge NIHR BRC Stratified Medicine Core Laboratory NGS Hub (supported by an MRC Clinical Infrastructure Award) for their support with whole blood RNA-Sequencing. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. K.G.C.S. is the recipient of a Wellcome Investigator Award (200871/Z/16/Z); M.P.W. is the recipient of Wellcome Senior Clinical Research Fellowship (108070/Z/15/Z); C.H. was funded by a Wellcome COVID-19 Rapid Response DCF and the Fondation Botnar; N.M. was funded by the MRC (CSF MR/P008801/1), NHSBT (WPA15-02) and Addenbrookes Charitable Trust (grant ref. to 900239 NJM); I.G.G. is a Wellcome Senior Fellow and was supported by funding from the Wellcome (Ref: 207498/Z/17/Z). P.J.L. is the recipient of a Wellcome Trust Principal Research Fellowship (084957/Z/08/Z) and MRC research grant (MR/V011561/1). NB and AP are supported by the Wellcome Trust, Senior Investigator Award to P.H.M, and the Rosetrees Trust. NR is supported by the NIHR Cambridge Biomedical Research Centre. Z.K.T. and M.R.C. are supported by a Medical Research Council Human Cell Atlas Research Grant (MR/S035842/1). M.R.C is supported by an NIHR Research Professorship (RP-2017-08-ST2-002). PK is the recipient of a Jacquot Research Entry Scholarship of the Royal Australasian College of Physicians Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the East of England, Cambridge Central Research Ethics Committee (NIHR BioResource REC ref 17/EE/0025, and Genetic variation AND Altered Leucocyte Function in health and disease, GANDALF REC ref 08/H0308/176). All participants provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset from our study can be explored interactively through a web portal: https://covid19cellatlas.org. https://covid19cellatlas.org.